Equillium, Inc. (EQ) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $1.96, EQ has negative trailing earnings (P/E not meaningful) and an ROE of -41.15%. Market capitalisation stands at $124M.
Balance sheet quality for EQ: current ratio of 10.3, net cash position of $29.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.96 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.77 |
| EV / EBITDA | -5.22 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -41.15% |
| Return on Invested Capital | -34.10% |
| Return on Assets | -30.70% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 23.40 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| EQ | Equillium, Inc. | $119M | 3.77 | -41.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | 18.85 | 2.57 | 13.8% |
| REGN | Regeneron Pharmaceuticals, Inc. | $80.5B | 18.53 | 2.53 | 13.8% |
| ARGX | argenx SE | $61.2B | 35.90 | 7.32 | 21.7% |
| MRNA | Moderna, Inc. | $57.0B | 8.53 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $43.3B | 16.16 |
Price Performance
| 1 month | -15.67% |
| 3 months | -35.57% |
| Year-to-date | +26.77% |
| 1 year | +31.00% |
| 3 years | +144.52% |
52-Week Range
| 52-week High | $3.54 |
| 52-week Low | $0.76 |
| Avg Volume (90d) | 731K |
Related companies: COEP · CUE · FBIO · IPSC · MDCX · NRXP · OSTX
Explore sector: Healthcare · Biotechnology
More sections of EQ: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks